Clinical profile and outcome of patients with chronic inflammatory arthritis and metabolic syndrome

Giovanni Cioffi1 · Ombretta Viapiana1 · Luigi Tarantini2 · Giovanni Orsolini1 · Luca Idolazzi1 · Federica Ognibeni Sonographer · Andrea Dalbeni3 · Davide Gatti1 · Angelo Fassio1 · Maurizio Rossini1 · Alessandro Giollo1

Received: 20 June 2020 / Accepted: 25 September 2020 / Published online: 20 October 2020
© The Author(s) 2020

Abstract
Systemic chronic inflammation may favor the onset of metabolic syndrome (MetS) which represents a risk factor for CV events. Rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) are disorders with high prevalence of MetS. We assessed the factors associated with MetS and its prognostic role in non-selected RA/AS/PsA patients. Between March 2014 and April 2016, 458 patients (228 RA, 134 PsA, 96 AS) selected for a primary prevention program for cardiovascular diseases were analyzed. Primary and co-primary end points were a composite of all-cause death/all-cause hospitalization and CV death/CV hospitalization, respectively. MetS was diagnosed according to the IDF Task Force on Epidemiology and Prevention. Patients were divided into MetS+ (73 = 16%) and MetS− (385 = 84%). At multivariate logistic analysis, cancer, moderate/high disease activity, higher LV mass (LVM) and degree of LV diastolic dysfunction were independently associated with MetS. At 36-month follow-up, the event rate for primary/co-primary end point was 52/15% in MetS+ vs 23/7% in MetS− (both \( p < 0.001 \)). At multivariate Cox regression analysis, MetS was related to primary end point (HR 1.52 [CI 1.01–2.47], \( p = 0.04 \)) together with higher LVM, disease duration and higher prevalence of biologic DMARDs refractoriness, and to co-primary end point (HR 2.05 [CI 1.16–3.60], \( p = 0.01 \)) together with older age and higher LVM. The RA/AS/PsA phenotype MetS+ is a subject with moderate/high disease activity, LV structural and functional abnormalities at increased risk for cancer. MetS+ identifies RA/AS/PsA patients at higher risk for CV and non-CV events, independently of traditional CV risk factors analyzed individually and traditional indexes of inflammation.

Keywords Metabolic syndrome · Rheumatoid arthritis · Psoriatic arthritis · Ankylosing spondylitis · Clinical outcomes · Cardiovascular risk factors · Cancer · Prognosis

Introduction
Metabolic syndrome (MetS) represents a cluster of cardiometabolic disorders including obesity and visceral adiposity, insulin resistance, dyslipidemia, hyperglycemia and hypertension. Scientific evidence has eliminated legitimate doubts about the association between MetS and adverse prognosis in a number of clinical settings, with special emphasis on those with high prevalence and public health impact such as cardiovascular (CV) morbidity and mortality [1–5]. However, there is still debate in the scientific community about whether MetS facilitates the prediction of adverse clinical events beyond use of single risk factors [6–8], also in relation to the different definitions of MetS itself [9, 10]. It has been clearly documented that MetS is associated with more severe left ventricular (LV) hypertrophy and other manifestations of preclinical CV disease [11, 12], while conflicting results exist about its influence on LV systolic function [13, 14]. Collectively, available data from the literature suggest that the CV risk predicted by MetS might be mediated, at least in part, by changes in LV geometry, diastolic function [15] and increased aortic stiffness [16, 17]. Systemic chronic
inflammation and the increased production of pro-inflammatory cytokines may favor the onset of MetS [18–21]. This is the reason why patients with chronic inflammatory arthritis such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) have increased prevalence of MetS [22–24]. Furthermore, in these patients, the activation of pro-inflammatory signaling pathways stimulates several biological markers of inflammation contributing to CV disease. Thus, MetS and altered secretion patterns of pro-inflammatory molecules could be the link between chronic inflammatory arthritis and CV diseases. Although intuitive and rational, this association has never been demonstrated in the setting of patients with chronic inflammatory arthritis. Furthermore, it is still uncertain whether MetS represents an adverse risk factor for the occurrence of adverse clinical events in patients with chronic inflammatory arthritis such as RA/AS/PsA. Accordingly, this study aimed to assess the prevalence and factors related to MetS in patients suffering from RA/AS/PsA, and to evaluate whether MetS is associated with more incident CV and/or non-CV events, independent of the traditional CV risk factors analyzed individually (including LV hypertrophy) and of traditional markers of inflammation and disease activity.

**Materials and methods**

**Study population**

The design of the study was prospective. The study population comprised non-institutionalized subjects > 18 years of age in stable sinus rhythm with RA diagnosed according to the 2010 ACR/EULAR classification criteria [25], PsA and AS diagnosed by the CASPAR and the ASAS criteria as recently summarized by Rudwaleit and Taylor [26]. Participants were consecutively recruited from March 2014 to April 2016 at the Division of Rheumatology, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona (Italy). They underwent clinical, laboratory and echocardiographic evaluations as part of a primary prevention program for CV diseases. Exclusion criteria were the presence of symptoms/signs of cardiac disease, a history of myocardial infarction, myocarditis or heart failure, coronary heart disease diagnosed by clinical, electrocardiographic evaluation at rest and by the results of exercise/scintigraphy/echo-stress test, alcoholic or primary hypertrophic cardiomyopathy, prior myocardial revascularization, significant valve heart disease and atrial fibrillation. All patients gave written informed consent signing a specific institutional consent form; the study was approved by Ethical Committees of the Verona University and conforms to the ethical guidelines of the Declaration of Helsinki as revised in 2000.

**Definitions**

Metabolic syndrome was diagnosed according to the joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention (National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity) [10] when three or more of the five conditions listed below were present (this definition recognizes that the risk associated with a particular waist measurement differs in different populations):

- Abdominal obesity defined as waist circumference > 102 cm in men and > 88 cm in women.
- Triglycerides ≥ 150 mg/dl.
- HDL cholesterol < 40 mg/dl for men and < 50 mg/dl for women.
- Blood pressure ≥ 130/ ≥ 85 mmHg.
- Fasting glucose ≥ 100 mg/dl (this condition was satisfied in patients with diabetes mellitus by definition).

Hypertension was defined as a resting blood pressure greater than 140 mmHg systolic and/or greater than 90 mmHg diastolic on at least two occasions or current anti-hypertensive pharmacological treatment. Obesity was recognized when body mass index ≥ 30 kg/m². Dyslipidemia was defined as levels of total serum cholesterol > 190 mg/dl and or triglycerides > 150 mg/dl or pharmacologically treated high lipid serum levels. Fasting plasma glucose level of 7.0 mmol/l (126 mg/dl) or greater or treatment with oral hypoglycemic agent and/or insulin identified patients with diabetes mellitus. Renal function was assessed calculating the glomerular filtration rate (GFR) estimated by the CKD-EPI equation. Ischemic stroke was defined as a focal neurological deficit of sudden onset as diagnosed by a neurologist, lasting more than 24 h and caused by ischemia; transient ischemic attack (TIA) was defined as a focal neurological deficit of sudden onset and diagnosed by a neurologist, lasting less than 24 h; thromboembolism (TE) was defined as the occlusion of blood flow by an embolus, outside the brain and heart by the responsible physician. To stratify individuals according to the magnitude of risk for CV adverse clinical events, we used the “Italian Progetto CUORE risk score” which was built specifically for the Italian population miming the Framingham experience using data from different cohorts enrolled in the north, center and south of Italy between the 1980s and the 1990s, whose risk factors had been collected using standardized procedures [27]. A score > 2.5% identified subjects at moderate/high CV risk. The Charlson index was calculated in each patient to evaluate the degree of comorbidity/frailty [28]. We defined...
patients as biologic disease-modifying anti-rheumatic drugs (DMARDs) refractory on the date they had started their third class of biologic DMARDs before the enrollment into the study [29]. The degree of disease activity was evaluated by the clinical disease activity index (CDAI) score [30]. Patients with a CDAI score > 10 were defined as subjects with activated pattern of the disease having moderate-high disease activity.

**Echocardiography**

Transthoracic Doppler echocardiography was performed following a standardized protocol. LV mass was calculated using the Devereux’s formula and normalized for height to the 2.7 power; LV hypertrophy was defined as LV mass > 49.2 g/m^2.7 for men and > 46.7 for women [31]. LV end-diastolic and end-systolic volumes were measured by the biplane method of disks from 2D apical 4 chamber + 2 chamber views and used to calculate ejection fraction. Assessment of LV diastolic function was based on widely accepted diastolic function parameters and LV diastolic dysfunction was recognized using validated cutoffs of prognostic relevance, as previously reported [32].

**Outcomes and follow-up**

The pre-specified primary end point of the study was a composite of all-cause death/all-cause hospitalization. Co-primary end point was a composite of CV death/CV hospitalization due to both cardiac events (unstable angina, myocardial infarction, severe chest pain due to acute pericarditis, heart failure, percutaneous coronary intervention and coronary artery bypass grafting) and vascular events (stroke, TIA, TE, peripheral vascular intervention and stent thrombosis). For each patient, the follow-up was stopped at the time of the first (CV or non-CV) event. All clinical events were examined by an independent end-point classification committee. Each clinical event was diagnosed and classified by two expert clinicians who analyzed in detail the clinical reports, validated the end points and formally generated the information which migrated into the database. Hospitalizations and vital status were recorded every 3 months during the scheduled visits for clinical check or during hospital access for therapy with biologic DMARDs or by telephone calls. Follow-up ended on 30 April 2019. All anamnestic data and those gathered during follow-up were recorded in the patient’s e-chart and then subsequently migrated to the data warehouse.

**Statistical analysis**

Data are reported as mean values ± 1 standard deviation (medians and interquartile ranges for variables deviating from normality) or percentages. Unpaired Student’s test and $\chi^2$ statistics were used for descriptive statistics. Between-group comparisons of categorical and continuous variables were performed by $\chi^2$ test and analysis of variance (ANOVA) with comparison between each group by Scheffè test for unequal sample, as appropriate or the Mann–Whitney non-parametrical test. Multivariate logistic regression analysis was performed to assess the factors independently associated with MetS. Log cumulative hazard functions were computed by univariate and multivariate Cox regressions to identify the factors independently associated with the study clinical end points. Variables that were significantly related to the study end point in univariate tests ($p \leq 0.05$) were included in the multivariable models, which also comprised those variables that were forced into the models for their specific clinical relevance. Probabilities of event-free survival and Kaplan–Meier survival curves of patients with vs those without MetS were obtained (differences between the curves were tested for significance by the Log-rank test). All analyses were performed using statistical package SPSS 19.0 (SPSS Inc. Chicago, Illinois, USA) and statistical significance was identified by two-tailed $p < 0.05$.

**Results**

**Study population**

The initial study population comprised 468 subjects. Among these patients, 10 (2%) were lost to the follow-up leaving 458 patients (228 RA, 96 AS, 134 PsA) who had complete clinical and follow-up data and formed the final population of the present study. Their baseline characteristics are shown in Table 1. Patients had a mean age of 58 ± 12 years, 63% were women, 16% obese. MetS was recognized in 73 subjects (15.6%). Prevalence of MetS was similar between patients with RA (34 of 228 = 15%), PsA (25 of 134 = 19%) and AS (14 of 96 = 15%; all $p$ between the groups > 0.1).

**MetS and study groups**

The baseline clinical features of the 73 patients who had MetS were compared with those of 385 patients who had not (Table 1). The former were older, with a higher prevalence of all CV risk factors (but smoking and renal dysfunction), cancer, higher markers and scores of disease activity, and higher LV mass than the latter. Furthermore, patients with MetS were taking at enrollment more frequently drugs for the control of the CV risk factors, more frequently
Table 1  Baseline characteristics of the study population divided into two subgroups according to the presence/absence of metabolic syndrome

| Variables                          | MetS No 385 patients | MetS Yes 73 patients | p       | Total study population 458 patients |
|------------------------------------|----------------------|----------------------|---------|-----------------------------------|
| Age (years)                        | 57 ± 13              | 62 ± 11              | < 0.001 | 58 ± 12                           |
| Female gender (%)                  | 63                   | 61                   | 0.66    | 63                                |
| Body mass index (Kg/height^2)      | 25.3 ± 4.0           | 29.4 ± 5.3           | < 0.001 | 25.9 ± 4.4                       |
| Waist circumference (cm)           | 90.9 ± 11.8          | 104.1 ± 12.2         | < 0.001 | 93.0 ± 12.8                      |
| Obese (%)                          | 12                   | 39                   | < 0.001 | 16                                |
| Systolic blood pressure (mmHg)     | 129 ± 16             | 145 ± 18             | < 0.001 | 131 ± 17                         |
| Diastolic blood pressure (mmHg)    | 82 ± 8               | 87 ± 9               | 0.04    | 82 ± 8                           |
| Hypertension (%)                   | 40                   | 80                   | < 0.001 | 46                                |
| Smoking (%)                        | 34                   | 34                   | 0.99    | 34                                |
| Dyslipidemia (%)                   | 54                   | 68                   | 0.03    | 57                                |
| Diabetes mellitus (%)              | 5                    | 30                   | < 0.001 | 9                                 |
| eGFR (ml/min/m^2*1.73)             | 94 ± 22              | 93 ± 28              | 0.58    | 94 ± 23                           |
| Hemoglobin (g/dl)                  | 13.9 ± 1.4           | 13.9 ± 1.6           | 0.80    | 13.9 ± 1.4                       |
| Glycemia (mg/dl)                   | 89.9 ± 15.4          | 116.1 ± 29.2         | < 0.001 | 95 ± 25                           |
| Cholesterol HDL (mg/dl)            | 65 [48–82]           | 52 [32–68]           | < 0.001 | 61 [49–73]                       |
| Cholesterol LDL (mg/dl)            | 123 [93–151]         | 120 [85–138]         | 0.58    | 121 [99–140]                      |
| Triglycerides (mg/dl)              | 106 [72–134]         | 182 [115–245]        | < 0.001 | 101 [74–139]                      |
| Progetto Cuore risk score (%)a     | 5.1 ± 3.9            | 12.2 ± 10.7          | < 0.001 | 6.3 ± 5.2                        |
| Moderate/high CV risk (%)          | 57                   | 82                   | < 0.001 | 61                                |
| Cancer (%)b                        | 6                    | 31                   | < 0.001 | 10                                |
| Charlson index (points)            | 2.4 ± 1.8            | 5.8 ± 2.4            | < 0.001 | 2.9 ± 2.2                        |
| C-reactive protein (mg/dl)         | 4.0 [2.5–7.1]        | 6.2 [3.8–9.9]        | 0.04    | 4.3 [2.8–7.8]                     |
| ESR (mm/h)                         | 19 [6, 29]           | 22 [11, 34]          | 0.22    | 15 [6, 27]                       |
| Rheumatoid factor positive (%)c    | 51                   | 47                   | 0.48    | 50                                |
| ACPA positive (%)c                 | 50                   | 46                   | 0.28    | 49                                |
| Duration of disease (years)        | 12.7 ± 9.8           | 12.2 ± 10.1          | 0.67    | 12.6 ± 9.9                       |
| CDAI†                              | 9.7 ± 8.9            | 13.7 ± 10.6          | 0.009   | 10.5 ± 8.4                       |
| Moderate/high disease activity (%) | 28                   | 48                   | < 0.001 | 32                                |
| LV mass (g/height^2.7)             | 43 ± 11              | 48 ± 12              | < 0.001 | 44 ± 11                           |
| E/E’ ratio                         | 6.2 ± 1.5            | 7.1 ± 2.3            | < 0.001 | 6.3 ± 1.7                        |
| LV diastolic dysfunction (%)       | 26                   | 39                   | 0.35    | 28                                |
| LVEF (%)                           | 66 ± 6               | 66 ± 6               | 0.35    | 66 ± 6                            |

Medications

- ACEi/ARBs (%) 23 56 < 0.001 28
- Beta-blockers (%) 13 33 < 0.001 16
- Diuretics (%) 13 27 0.002 15
- Calcium antagonists (%) 9 10 0.67 9
- Statins (%) 17 39 0.001 21
- Anti-platelet agents (n, %) 11 22 < 0.001 13
- NSAIDs (%) 36 30 0.38 35
- Methotrexate (%) 40 46 0.34 41
- Hydroxychloroquine (%) 8 6 0.69 8
- Corticosteroids (%) 36 30 < 0.001 35
- Biologic DMARDs at enrollment (%) 69 57 < 0.001 67

Biologic DMARDs class

- Anti-TNFα (%) 70 64 0.10 69
- Anti-interleukin 6 (%) 12 11 12
- CTLA4 Ig (%) 12 16 13
- Anti-CD 20 (%) 6 9 6
- Biologic DMARDs refractory (%) 28 30 0.79 28
corticosteroids and biologic DMARDs than patients without MetS. Prevalence of biologic DMARDs refractoriness was similar between the two groups.

Covariates of MetS

Variables significantly associated with MetS at univariate analysis are listed in the Table 2. Among this variables, age, cancer, C-reactive protein, moderate/high disease activity, LV mass and E/E′ ratio (parameter of LV diastolic function) were included in the multivariable logistic regression model. This analysis revealed that cancer, presence of moderate/high disease activity, higher LV mass and higher E/E′ ratio (index of higher degree of LV diastolic dysfunction) were the states independently associated with MetS in our patients.

Clinical outcomes

Data on vital status and hospitalizations were available for all 458 patients. During a median follow-up of 36 months (IQR 23–45), eight patients (1.7%) died. All of them died during hospitalization. Causes of death were cancer in four patients (pancreatic in 2 cases, breast and laryngeal in one case), and congestive heart failure, complications of pneumonia, femoral neck fracture and peripheral vascular surgery in the remaining four patients.

A primary end point (all-cause death/all-cause hospitalization) occurred in 128 patients (28%). A co-primary end point (CV death/CV hospitalization) occurred in 37 patients (8%). Considering the primary end point, the event rate at 36-month follow-up was 52% in the group with MetS (38 of 73 patients) vs 23% in the group without MetS (90 of 385 patients, p < 0.001). In regard to the co-primary end point CV death/CV hospitalization, the event rate was significantly higher in the former group (11 patients = 15%) than in the latter group (26 patients = 7%, p = 0.02), as well as for non-CV events (38% vs 16%, p < 0.001).

Reasons of the 128 all-cause hospitalizations, separated in 37 CV hospitalizations and 91 non-CV hospitalizations, are reported in Table 3. Causes of CV hospitalization did not substantially differ between patients with and without MetS. Among the causes of non-CV hospitalization, cancer (9 patients = 12.7% vs 2 patients = 0.5%, p < 0.001), bone fracture (5 patients = 7.0% vs 11 patients = 2.8%, p = 0.03), and hip/knee arthroplasty (4 patients = 5.6% vs 11 patients = 2.8%, p = 0.04) occurred more frequently in patients with than without MetS, respectively. No significant difference was recognized between the two groups for the other causes of non-CV hospitalization.

Table 1 (continued)

| Variables                        | Univariate analysis | Multivariate analysis |
|----------------------------------|---------------------|-----------------------|
|                                  | Odds ratio          | Confidence intervals  | p        | Odds ratio          | Confidence intervals | p        |
| Age (years)                      | 1.04                | 1.01–1.07             | 0.002    | 0.99                | 0.96–1.03             | 0.74     |
| Cancer (%)                       | 7.45                | 3.84–14.44            | <0.001   | 4.78                | 2.19–10.41            | <0.001   |
| C-reactive protein (mg/dl)       | 1.03                | 1.00–1.06             | 0.04     | 1.01                | 0.97–1.05             | 0.73     |
| CDAD (%)                         | 1.04                | 1.01–1.08             | 0.01     |                    |                       |          |
| Moderate/high disease activity (%) | 2.28                | 1.29–4.03             | 0.004    | 1.77                | 1.01–3.27             | 0.04     |
| LV mass (g/height²)              | 1.04                | 1.02–1.06             | <0.001   | 1.03                | 1.00–1.05             | 0.03     |
| E/E′ ratio                       | 1.33                | 1.13–1.52             | <0.001   | 1.19                | 1.02–1.40             | 0.04     |
| LV diastolic dysfunction (%)     | 1.78                | 1.05–3.04             | 0.03     |                    |                       |          |

a % Included patients in whom cancer was diagnosed during follow-up

b % Included patients in whom cancer was diagnosed during follow-up
c % Among patients with rheumatoid arthritis
d % Among patients who were receiving biologic DMARDs

Table 2 Variables significantly associated with metabolic syndrome: univariate and multivariate logistic regression analysis
MetS as prognosticator of adverse outcome

At univariate Cox regression, the variables associated with the primary study end point were hypertension, waist circumference, MetS, LV mass, duration of chronic inflammatory disease and biologic DMARDs refractoriness. All these variables together with age, which was forced into the model, were considered in the multivariate model. Multivariate Cox regression analysis revealed that MetS was independently related to the primary end point (HR 1.52 [CI 1.01–2.47], \( p = 0.04 \)), together with higher LV mass, longer duration of chronic inflammatory disease and higher prevalence of biologic DMARDs refractoriness (Table 4, upper part).

Considering the co-primary end point, the variables associated with the 37 adverse events at univariate Cox regression analysis were age, MetS, GFR, LV mass and E/E′, with hypertension, dyslipidemia and duration of chronic inflammatory disease, showing a borderline statistical significance. Multivariate Cox regression (including age, MetS, GFR, LV mass and E/E′) showed that MetS was independently related to CV death/CV hospitalization (HR 2.05 [CI 1.16–3.60], \( p = 0.01 \)), together with older age and higher LV mass (Table 4, lower part). Kaplan–Meier survival curves for primary end point of patients with MetS vs those without MetS are shown in Fig. 1. Figure 2 shows Kaplan–Meier survival curves of the two study groups for co-primary end point (right panel) and for non-CV events analyzed separately (left panel).

Discussion

Our study showed some original and clinically relevant results which have never been analyzed in depth in patients with chronic inflammatory arthritis: (1) MetS is recognized in a consistent proportion (around one-sixth) of subjects with RA/PsA/AS without overt cardiac disease selected for a primary prevention program for CV diseases; (2) in these patients, the presence of MetS is associated with cancer,
Table 4 Variables associated with the study end points: univariate and multivariable Cox regression analyses

| Endpoint                      | Yes     | No      | Univariate | HR   | CI    | p    | Multivariate | HR   | CI    | p    |
|-------------------------------|---------|---------|------------|------|-------|------|--------------|------|-------|------|
| All-cause death/hospitalization | 128 pts | 330 pts |            |      |       |      |              |      |       |      |
| Age (years)                   | 61 ± 12 | 56 ± 13 | 1.01       | 0.99–1.02 | 0.34 | 1.01 | 0.98–1.03 | 0.52 |
| Hypertension (%)              | 59      | 42      | 1.58       | 1.11–2.25 | 0.01 | 1.08 | 0.67–1.76 | 0.75 |
| Dyslipidemia (%)              | 67      | 52      | 1.30       | 0.90–1.90 | 0.16 |      |      |      |
| Waist circumference (cm)      | 96 ± 12 | 91 ± 13 | 1.02       | 1.01–1.04 | 0.001| 1.01 | 0.99–1.03 | 0.49 |
| Metabolic syndrome (%)        | 52      | 23      | 1.80       | 1.20–2.68 | 0.003| 1.52 | 1.01–2.47 | 0.04 |
| E/E′                          | 6.7 ± 1.9 | 6.1 ± 1.6 | 1.00       | 0.92–1.10 | 0.91 |      |      |      |
| Left ventricular mass (g/height²) | 47 ± 11 | 43 ± 11 | 1.01       | 1.00–1.03 | 0.04 | 1.02 | 1.00–1.05 | 0.02 |
| Disease duration (years)      | 15 ± 9  | 11 ± 7  | 1.02       | 1.00–1.04 | 0.04 | 1.02 | 1.00–1.04 | 0.02 |
| Biologic DMARDs refractory (%)| 39      | 23      | 1.71       | 1.14–2.58 | 0.01 | 1.66 | 1.07–2.57 | 0.03 |
| Cardiovascular death/hospitalization | 37 pts | 421 pts |            |      |       |      |              |      |       |      |
| Age (years)                   | 67 ± 11 | 57 ± 12 | 1.06       | 1.03–1.09 | < 0.001| 1.02 | 1.00–1.04 | 0.04 |
| Hypertension (%)              | 62      | 45      | 1.90       | 0.98–3.70 | 0.06 |      |      |      |
| Dyslipidemia (%)              | 72      | 55      | 1.92       | 0.92–3.99 | 0.07 |      |      |      |
| Metabolic syndrome (%)        | 15      | 7       | 2.14       | 1.12–4.68 | 0.01 | 2.05 | 1.16–3.60 | 0.01 |
| Glomerular filtration rate (ml/min/m²*1.73) | 83 ± 20 | 95 ± 23 | 0.98       | 0.96–0.99 | 0.02 | 1.00 | 0.99–1.01 | 0.76 |
| E/E′                          | 7.7 ± 2.5 | 6.2 ± 1.5 | 1.38       | 1.19–1.59 | 0.01 | 1.07 | 0.93–1.22 | 0.35 |
| Left ventricular mass (g/height²) | 53 ± 12 | 43 ± 11 | 1.04       | 1.02–1.06 | < 0.001| 1.03 | 1.00–1.06 | 0.02 |
| Disease duration (years)      | 16 ± 9  | 12 ± 7  | 1.03       | 0.99–1.06 | 0.06 |      |      |      |

Fig. 1 Kaplan–Meier survival curves from primary end point (all-cause death/hospitalization) of patients with metabolic syndrome (MetS) vs those without MetS. Total study population including 458 patients were analyzed.
presence of moderate/high disease activity, higher LV mass and E/E′ ratio (suggestive of higher degree of LV diastolic dysfunction) independently of the various components by which MetS is recognized; (3) MetS emerges by Cox regression analysis as a strong prognosticator of adverse clinical events at mid-term follow-up; (4) the relationship between MetS and poorer prognosis relates to both primary end point (all-cause death/all-cause hospitalization) and co-primary end point (CV death/CV hospitalization) and is independent of the traditional CV risk factors and to the markers/scores commonly used for grading the magnitude of inflammation.

MetS is a cluster of traditional risk factors including abdominal obesity, atherogenic dyslipidemia, hypertension, and insulin resistance [9, 10], all states having common metabolic pathways with chronic systemic inflammation. Thus, it is not surprising that the prevalence of MetS is significantly higher in patients with RA/PsA/AS as compared to the general population [22–24]. We demonstrated that RA/PsA/AS subjects with MetS have higher magnitude of inflammation and a fivefold risk of developing cancer compared with counterparts without MetS. Linear associations of single metabolic risk factors with risk of incident overall cancer has been found by Stocks et al. [33] and Nagel et al. [34] in pooled analyses of several community cohorts. Such associations were confirmed when a derived metabolic risk score of five metabolic factors was applied [35, 36]. However, chronic inflammatory arthritis predisposes to cancer [37] by the stimulation of B and T cells by various antigens activating pro-inflammatory/carcinogenic cytokynes and the use of immunosuppressive drugs [38, 39]. Collectively, our findings indicate that in patients with RA/PsA/AS, the relationship between higher magnitude of chronic inflammation and the risk of developing cancer is magnified by the presence of MetS.

Higher LV mass and degree of LV diastolic dysfunction are also conditions related to MetS in our patients as well as the development of cancer (as demonstrated in a recent study) [40]. In this view, it is well known that arterial hypertension, hyperglycemia, dyslipidemia and central obesity confer individually a clinically relevant pressure/volume overload on the CV system, an atherogenic and neuro-endocrine stimulus for excessive LV mass growth.

![Kaplan–Meier survival curves from co-primary end point of patients with metabolic syndrome (MetS) vs those without MetS (right panel). Left panel refers to the non-CV events occurred in the two groups analyzed in the study](image-url)
and alterations in LV diastolic properties. In subjects with MetS, these functional myocardial changes seem to result specifically from intrinsic cardiomyocyte alterations, irrespective of the myocardial interstitium (including fibrosis), as detected by cardiac magnetic resonance [41]. All together, these effects harmfully predispose to the development of subclinical structural and functional abnormalities of cardiac [11–15] and vascular function [16, 17], which herald subsequent adverse clinical events.

As a result, MetS is a powerful prognosticator for stroke and CV diseases [5, 11, 42–44], both in the general population [42, 43] and in some specific settings of patients such as those with arterial hypertension [12] and/or type 2 diabetes mellitus [44]. Furthermore, it has been associated with silent myocardial ischemia independent of essential hypertension [45]. However, exact information in regard to the prognostic role of MetS in patients with RA/AS/PsA is still lacking. In this study, we demonstrated that MetS is closely related to both all-cause and CV adverse events at mid-term, together with older age, longer disease duration, higher LV mass and biologic DMARDs refractoriness. In our experience, during 3 years of follow-up, an event leading to hospitalization for all causes or for CV cause occurred in more than half and one-sixth of our patients with MetS, respectively. Our results are in line with those of Rutter et al. [42], showing that MetS predicted CV events in the community population analyzed in the Framingham Offspring Study. Similar data emerged in the prospective study of Santaniemi et al. [5], who analyzed 1004 Finnish subjects showing after 18 years of observation a 2.01-fold higher probability for any CV event in individuals who had MetS compared with those who had not. The hazard ratio raised to 7.89 in the subgroup of patients in whom all five components of MetS were present.

It has been clearly demonstrated that the main metabolic alterations induced by MetS correlate with an increased production of some cytokines (i.e., TNF-α, IL-6), which interfere with adipocyte metabolism both in patients with and without chronic inflammatory arthritides [46, 47]. All these abnormalities lead to decreased rates of glucose oxidation and non-oxidative glucose disposal, high rates of lipid oxidation, adhesion molecules [48] and faster progression of atherosclerotic damage [49]. Although data on serum cytokines levels were not available, these conditions may possibly represent reasons why our patients with RA/AS/PsA and MetS have lower threshold of myocardial or arterial ischemia and higher CV event rate.

Of interest, besides the higher incidence of CV events, patients who had MetS showed an increased event rate for non-CV death/hospitalization (more than 2-fold higher) than those who had not. This finding suggests that MetS is not a mere expression of the pathophysiologic mechanisms associated with RA/AS/PsA disease and/or a CV risk factor, but an influential marker of frailty and an indicator of more advanced stage of inflammatory disease predisposing to adverse clinical events. The very large difference in the Charlson comorbidity index between patients with and without MetS supports this concept.

**Study limitations and strengths**

Although prospective, our data were collected by a single center, so that some selection bias may have influenced the selection of patients. Secondly, the results of the present study might be prejudiced by the relatively small number of patients and/or CV events. Otherwise, the study strengths consist of the complete nature of the data set, the prospective gathering of quite a lot of variables traditionally related to CV and non-CV events, the use of a clinical, simple, feasible and validated definition on MetS and the accessibility to all prognostic information.

**Conclusions**

Chronic inflammatory arthritis including RA, AS and PsA are conditions at increased risk of morbidity and mortality for which a prognostic assessment for supporting an effective clinical management is mandatory. MetS is frequent in these patients, being closely and directly related to chronic inflammation and disease activity. It is associated with cancer, presence of moderate/high disease activity, LV structural and functional abnormalities, and is an independent prognosticator of adverse clinical events at mid-term follow-up. In light of our results, an increasingly accurate assessment of MetS should be routinely conducted in patients with RA/AS/PsA as a measure of clinical outcomes which goes beyond the role of simple CV risk factor. Beside this, prospective investigations aimed to assess the potential favorable role of anti-IL-6/anti-TNF-α biologic DMARDs on the development and/or on the detrimental effect of MetS would be appropriate.

**Acknowledgements** Not applicable.

**Author contributions** Conception and design: Giovanni Cioffi, Luigi Tarantini, Ombretta Viapiana, Federica Ogniben, Maurizio Rossini. Generation of clinical data: Giovanni Cioffi, Ombretta Viapiana, Luigi Tarantini, Federica Ogniben, Andrea Dalbeni, Alessandro Giotto, Giovanni Orsolini, Luca Idolazzi, Angelo Fassio, Davide Gatti, Maurizio Rossini. Analysis and interpretation of data, or both: Giovanni Cioffi, Ombretta Viapiana, Luigi Tarantini, Federica Ogniben, Andrea Dalbeni, Alessandro Giotto, Giovanni Orsolini, Luca Idolazzi, Angelo Fassio, Davide Gatti, Maurizio Rossini. Drafting of the manuscript or revising it critically for important intellectual content: Giovanni Cioffi, Ombretta Viapiana, Luigi Tarantini, Federica Ogniben, Andrea Dalbeni, Alessandro Giotto, Giovanni Orsolini, Luca Idolazzi, Angelo Fassio, Davide Gatti, Maurizio Rossini. Final approval of the manuscript submitted: Giovanni Cioffi, Ombretta Viapiana, Luigi Tarantini.
Federica Ognibeni, Andrea Dalbeni, Alessandro Giollo, Giovanni Orsolini, Luca Idolazzi, Angelo Fassio, Davide Gatti, Maurizio Rossini.

**Funding** Open access funding provided by Università degli Studi di Verona within the CRUI-CARE Agreement. No source of funding to declare.

**Compliance with ethical standards**

**Conflict of interest** All the authors declare that no conflict of interest exists (no relationship with industry or financial associations poses a conflict of interest in connection with the present study). No author received any financial support or other benefits from commercial sources for this work.

**Ethics approval and consent to participate** All patients gave written informed consent, signing a specific institutional consent form. The study was approved by the Ethical Committees of the Verona University and conforms to the ethical guidelines of the Declaration of Helsinki as revised in 2000.

**Consent to publication** Not applicable (the manuscript does not contain any individual person’s data.

**Availability of data and supporting materials section** Data sharing not applicable to this article; please contact the corresponding author for data requests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709–2716
2. Malik S, Wong ND, Franklin SS, Kamath TV, L’Italien GJ, Pio JR, Williams GR (2004) Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110:1245–1250
3. Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C, Mannarino E (2004) Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 43:1817–1822
4. Grassi G, Quarti-Trevano F, Seravalle G, Dell’Oro R (2007) Cardiorespiratory risk and adrenergic overdrive in the metabolic syndrome. Nutr Metab Cardiovasc Dis 17:473–481
5. Santaniemi M, Ulkkola O, Malo E, BiloJu R, Kesäniemi YA (2014) Metabolic syndrome in the prediction of cardiovascular events: the potential additive role of hsCRP and adiponectin. Eur J Prev Cardiol 21:1242–1248
6. Kahn R, Buse J, Ferrannini E, Stern M (2005) The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28:2289–2304
7. Reilly MP, Rader DJ (2003) The metabolic syndrome: more than the sum of its parts? Circulation 108:1546–1551
8. Ahmadi A, Leipsic J, Feuchtner G, Gransar H, Kalra D, Heo R, Achenbach S, Andreini D, Al-Mallah M, Berman DS, Budoff M, Cademartiri F, Callister TQ, Chang HJ, Chinnaikyan K, Chow B, Curv RC, Delago A, Gomez MJ, Hadamitzky M, Hausleiter J, Hindoyan N, Kaufmann PA, Kim YJ, Lin F, Maffei E, Pontone G, Raff GL, Shaw LJ, Villines TC, Dunning A, Min JK (2015) Is metabolic syndrome predictive of prevalence, extent, and risk of coronary artery disease beyond its components? Results from the multinational coronary CT angiography evaluation for clinical outcome: an international multicenter registry (CON-FIRM). PLoS ONE 10:e0118998. https://doi.org/10.1371/journal.pone.0118998
9. de Simone G, Devereux RB, Chinali M, Best LG, Lee ET, Galloway JM, Resnick HE (2007) Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the strong heart study. Diabetes Care 30:1851–1856
10. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr, International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, and International Association for the Study of Obesity. Circulation 120:1640–1645
11. Chinali M, Devereux RB, Howard BV, Roman MJ, Bella JN, Liu JE, Resnick HE, Lee ET, Best LG, de Simone G (2004) Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study). Am J Cardiol 93:40–44
12. de Simone G, Devereux RB, Chinali M, Roman MJ, Lee ET, Resnick HE, Howard BV (2009) Metabolic syndrome and left ventricular hypertrophy in the prediction of cardiovascular events: the Strong Heart Study. Nutr Metab Cardiovasc Dis 19:98–104
13. Tadic M, Cuspidi C, Majstorovic A, Pencic B, Backovic S, Ivanovic B, Scepanovic R, Martinov J, Kocijanvic V, Celic V (2014) Does the metabolic syndrome impact left-ventricular mechanics? A two-dimensional speckle tracking study. J Hypertens 32:1870–1878
14. Faganello G, Cioffi G, Faggiano P, Candido R, Tarantini L, De Feo S, Di Lenarda A, de Simone G (2015) Does metabolic syndrome worsen systolic dysfunction in diabetes? The shortwave study. Acta Diabetol 52:143–151
15. Tadic M, Ivanovic B, Kostic N, Simic D, Matic D, Celic V (2012) Metabolic syndrome and left ventricular function: is the number of criteria actually important? Med Sci Monit 18:282–289
16. Mule G, Cottone S, Mongiorgi R, Cusimano P, Mezzatenda G, Seddio G, Volpe V, Nardi E, Andronico G, Piazza G, Cerasola G (2006) Influence of the metabolic syndrome on aortic stiffness in never treated hypertensive patients. Nutr Metab Cardiovasc Dis 16:54–59
17. Iannuzzi A, De Michele M, Bond MG, Sacchetti L, Fortunato G, Salvatore F, Mattiello A, Panico S, Rubba P (2005) Carotid artery remodeling in middle-aged women with the metabolic syndrome (from the “Progetto ATENA” study). Am J Cardiol 96:1162–1165
molecules in subjects with metabolic syndrome. Circulation 110:3842–3848
49. Luna-Luna M, Medina-Urrutia A, Vargas-Alarcón G, Coss-Roviroa F, Vargas-Barrón J, Pérez-Méndez Ó (2015) Adipose tissue in metabolic syndrome: onset and progression of atherosclerosis. Arch Med Res 46:392–407

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.